Immunoradiometric and Immunohistochemical Demonstration of Neuron-Specific Enolase in Experimental Rat Gliomas1

Total Page:16

File Type:pdf, Size:1020Kb

Immunoradiometric and Immunohistochemical Demonstration of Neuron-Specific Enolase in Experimental Rat Gliomas1 [CANCER RESEARCH 44, 2595-2599, June 1984] Immunoradiometric and Immunohistochemical Demonstration of Neuron-specific Enolase in Experimental Rat Gliomas1 Stanley A. Vinores,2 Paul J. Marangos, Jose M. Bonnin,3 and Lucien J. Rubinstein Division of Neuropathology, Department ol Pathology, University of Virginia School of Medicine, Charlottesville, Virginia 22908 [S. A. V., J, M. B., L J. R.], and Biological Psychiatry Branch, National Institute of Mental Health, NIH, Bethesda, Maryland 20205 [P. J. M.J ABSTRACT demonstration of NSE in the tumors obtained following their i.e. inoculation. A number of ENU-induced neural tumors in rats were A number of neural and nonneural tumor cell lines of rat and also examined immunohistochemically for the presence of NSE. human origin were assayed for neuron-specific enolase (NSE) by radioimmunoassay. Most neural tumor cell lines had appreciably MATERIALS AND METHODS higher levels of NSE than did the nonneural tumor cell lines, the highest levels being found in two anaplastic rat glioma lines (F98 Cell Lines. A number of neural and extraneural tumor cell lines of rat and T24). These two lines contained more than twice the amount and human origin were obtained (see Tables 1 and 2) for the determi of NSE found in a rat pheochromocytoma line (PC12) and in nation of their NSE content. The tumors from which the rat lines were neuroblastoma lines derived from rats (B35 and B50) or humans derived included anaplastic gliomas, malignant schwannomas, spongio- (IMR-32 and SHSY-5Y). Several of the rat glioma and schwan- blastoma, astrocytomas, mixed gliomas, neuroblastomas, pheochromo noma lines were inoculated intracerebrally into syngeneic rats. cytoma, hepatoma, and mammary adenocarcinoma. The human lines In the resulting tumors, NSE was demonstrable by immunohis- were derived from 2 neuroblastomas and one mammary adenocarci noma. Lines C6 and IMR-32 were obtained from the American Type tochemistry only in those from the F98 and T24 cell lines. A Culture Collection (Rockville, MD); line SHSY-5Y from Dr. J. Biedler (New number of ethylnitrosourea-induced rat tumors were also ex York, NY); clone PC12 from Dr. R. Goodman (Philadelphia, PA); clones amined immunohistochemically for NSE: NSE was demonstrated F98 and D74 from Dr. W. Wechsler (Dusseldorf, Germany); lines B35 in three anaplastic gliomas; three astrocytomas; and two mixed and 850 from Dr. D. Schubert (San Diego, CA); lines T9, T13, TU, T22, gliomas. Reactive astrocytes were also positive. Fibroadenomas T24, Y1196, Y2116, Y2121, 78-3853, 78-3864, and 78-4836 from Dr. of apocrine and mammary glands in rats were weakly positive, A. Koestner (East Lansing, Ml); line Q7 from Dr. J. Chou (Bethesda, MD); but other extraneural tumors tested were negative. and lines 64/24 and MCF7 from Dr. C. Eil (Bethesda, MD). Since normal neuronal elements, axonal swellings, and amine Inoculations i.e. of Tumor Cell Lines. Nine of the glioma lines and 2 precursor uptake and decarboxylation cells are strongly positive of the schwannoma lines (Table 1) were inoculated i.e. into the brains of syngeneic male Fischer rats weighing 90 to 110 g (Charles River, for NSE, whereas glia and most other normal cells are negative, Portage, Ml) as described previously (35). PC12 cells were inoculated in we hypothesize that the elevated metabolic demands imposed the same manner into New England Deaconess rats (Deaconess Hospi on neoplastic and reactive glial cells and on some extraneural tal, Boston, MA). Some of these rats were inoculated s.c. with PC12 tumors necessitate the opening up of metabolic pathways that cells for comparison. The tumor-bearing brains and, when present, the are normally operative only in neurons and neuroendocrine cells, visceral métastases, as well as s.c. PC12 pheochromocytomas, were therefore resulting in the synthesis of the more stable neuron- fixed by immersion in 10% buffered formalin after necropsy. specific form of enolase. Induction of Tumors by ENU. Tumors were induced transplacentally by a single injection of 20-mg/kg body weight of ENU in citrate buffer, pH 4.5, via the sciatic vein of pregnant Fischer rats on the 18th day of INTRODUCTION gestation or of ENU, 50 mg/kg, via the tail vein on the 16th day of NSE4 has been reported to be uniquely contained in all classes gestation. The tumors that developed in the offspring, usually between 150 and 500 days after birth, were fixed as described above after the of neurons (13, 21, 26) and in normal and neoplastic cells of the rats were sacrificed or had died from their tumors. APUD system (4, 5, 8,19, 25, 27, 30, 40, 41). Its appearance in Perfused Normal Rat Tissues. Normal rat tissues were fixed for 48 normal conditions correlates directly with structural and func hr at room temperature in 10% buffered formalin after intraventricular tional neurogenesis (15,25,37), and the enzyme levels detected gravity perfusion, first briefly with phosphate-buffered saline (0.01 M have been used as an index for neuronal differentiation (11, 19, phosphate buffer, pH 7.6, containing 0.85% NaCI) and then with 10% 25, 39). It is absent from normal glia (21, 24). The purpose of buffered formalin for about 10 min, both at 37°C. this study was to determine by immunoradiometric assay the RIA. Cultured cells from the various cell lines tested (Tables 1 and 2) were washed with Ca2+-, Mg2+-free Dulbecco's phosphate-buffered sa levels of NSE in a variety of rat glioma and schwannoma cell line (0.2 g KCI:0.2 g KH2PO«:8g NaCI:2.16 g Na2HPO4-7H2O/liter) and lines and to correlate these levels with the immunohistochemical immediately frozen on dry ice in 107 cell aliquots. These were homoge ' Supported by Research Grant CA 31271 of the National Cancer Institute and nized and assayed for NSE using a double-antibody, solid-phase RIA by Neuropathology Research Training Grant T32 NSO7236 of the National Institute procedure as described previously (14, 20, 39). Assays were done in of Neurological and Communicable Diseases and Stroke, United States Department triplicate for each cell line. Cells from rat tumor lines were assayed with of Health and Human Services. 2To whom requests for reprints should be addressed. anti-rat NSE antiserum, and those from human lines were assayed with 3 Recipient of Clinical Fellowship 5732 of the American Cancer Society. anti-human NSE antiserum. Antisera were produced as described pre 4 The abbreviations used are: NSE, neuron-specific enolase; APUD, amine viously (17). precursor uptake and decarboxylation; GFA, glial tibnllary acidic; RIA. radioimmu Immunohistochemistry. All tissues from the i.e. implants and ENU- noassay; ENU, ethylnitrosourea; TBS:NGS, 0.05 M Tris buffer, pH 7.6, containing 0.9% NaCI solution and 1% normal goat serum; i.e., intracerebral(ly). induced tumors, as well as normal rat tissues, were embedded in paraffin, Received November 22, 1983; accepted February 24, 1984. sectioned, and stained for NSE by the peroxidase:antiperoxidase tech- JUNE 1984 2595 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1984 American Association for Cancer Research. S. A. Vinares et al. Tabtel with fresh buffered saline (except after the last centrifugation). Diluted Detection of NSE in rat neural tumors by RIA and peroxidase:antiperoxidase anti-NSE serum was added to the pellet in a ratio of 1 ml of 1:500 Cultured cells were assayed by RIA for NSE In aliquots of 107 cells. The standard antiserum/100 mg of washed liver powder (dry weight). This was incu curve for NSE detection ranged from 100 pg to 5 ng (20). The minimal detectable bated for 30 min at 37°and centrifuged as above. The supernatant was level was 100 pg/ml of solution. The resulting tumors were assayed by peroxi- dase:antiperoxidase following I.e. inoculation of these cells. Paraffin-embedded added to 50 mg of washed liver powder (dry weight)/ml, incubated, and sections were incubated with a 1:500 dilution of rabbit anti-rat NSE serum. centrifuged as before. The supernatant was then applied to deparaffin- ized sections as described above. of NSE by from which the NSE levels in out- peroxidase: cell tured cells (ng/mg antiperoxidase in CelllineF98T24T9Y211678-3864T13Y1196T22Y2121C6T1478-385378-4836D74PC12TumorderivedAnaplastialine was implants1407.1protein) i.e. RESULTS gliomaAnaplastic ±1330.0 glioma0Anaplastia Radioimmunoassay ±751 gliomaAnaplastic .3±61 gliomaMalignant 2.2±271.1 The quantitative values for NSE obtained from several cultured schwannomaMalignant ±754.9 lines of neural tumors (Tables 1 and 2) ranged from a low of schwannomaMalignant ±373.4 schwannomaSpongioblastomaAstrocytomaAstrocytomaMixed±741 267.7 ±75.6 (S.D.) ng/mg protein in the C6 astrocytoma to a .7±470.1 high of 1407.1 ± 102.8 ng/mg protein in the F98 anaplastic ±267.7 glioma. Most neural tumor lines had NSE levels that were appre ±1041.7 gliomaMixed ±421 ciably higher than those of the 3 nonneural tumors examined. gliomaMixed .6±289.8 However, the cells from one rat malignant schwannoma, 2 rat gliomaDifferentiated ±820.4 gliomas (including the C6 astrocytoma), and one human neuro gliomaPheochromocytomaDetection±649.1 ±102.8a58.817.96.14.214.222.626.221.375.65.428.12.335.244.9+"+————NT———NT——NT-blastoma had low levels of NSE that were within the range of ' Mean ±S.D. that of the rat hepatoma. " +, positive; -, negative; NT, not tested. c The T24 line was derived from a tumor which was originally diagnosed as an Immunohistochemistry astrocytoma, but the absence of GFA protein in the implants grown after numerous in vitro passages has prompted us to call the tumor an anapìasticglioma. Controls. No staining was seen in any tissue when normal Table 2 rabbit serum was substituted for NSE antiserum.
Recommended publications
  • CCR7 Antibody (Y59) NB110-55680
    Product Datasheet CCR7 Antibody (Y59) NB110-55680 Unit Size: 0.1 ml Store at -20C. Avoid freeze-thaw cycles. Publications: 9 Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB110-55680 Updated 5/28/2019 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB110-55680 Page 1 of 6 v.20.1 Updated 5/28/2019 NB110-55680 CCR7 Antibody (Y59) Product Information Unit Size 0.1 ml Concentration This product is unpurified. The exact concentration of antibody is not quantifiable. Storage Store at -20C. Avoid freeze-thaw cycles. Clonality Monoclonal Clone Y59 Preservative 0.01% Sodium Azide Isotype IgG Purity Tissue culture supernatant Buffer 49% PBS, 0.05% BSA and 50% Glycerol Target Molecular Weight 45 kDa Product Description Host Rabbit Gene ID 1236 Gene Symbol CCR7 Species Human, Mouse, Rat, Monkey Reactivity Notes May cross reacts with Rhesus monkey. Specificity/Sensitivity The antibody does not cross-react with other G-protein coupled receptor 1 family members. Immunogen A synthetic peptide corresponding to residues in N-terminal extracellular domain of human CKR7 was used as immunogen. Notes Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487. Product Application Details Applications Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry- Paraffin, Immunoprecipitation, Flow Cytometry (Negative) Recommended Dilutions Western Blot 1:1000-10000, Immunohistochemistry 1:10-1:500, Immunocytochemistry/Immunofluorescence 1:250, Immunoprecipitation 1:10, Immunohistochemistry-Paraffin 1:250, Immunohistochemistry-Frozen 1:250, Flow Cytometry (Negative) Application Notes This product is useful for: Western Blot, Immunohistochemistry-Paraffin, Immunocytochemistry, Immunoprecipitation.
    [Show full text]
  • Memoranaurns by the Participants in Signes Par Les Partici- I the Meeting
    Memoranda are state- Les Memorandums ments concerning the exposent les conclu- /e , conclusions or recom- sions et recomman- M e mmooranrantedaa mendations of certain dations de certaines / a t w / /WHO scientific meet- /reunions scientifiques ings; they are signed de /'OMS; ils sont Memoranaurns by the participants in signes par les partici- I the meeting. pants a ces reunions. Bulletin ofthe World Health Organization, 62 (2): 217-227 (1984) © World Health Organization 1984 Immunodiagnosis simplified: Memorandum from a WHO Meeting* Technologies suitable for the development ofsimplified immunodiagnostic tests were reviewed by a Working Group of the WHO Advisory Committee on Medical Research in Geneva in June 1983. They included agglutination tests and use ofartificialparticles coated with immunoglobulins, direct visual detection of antigen-antibody reactions, enzyme- immunoassays, and immunofluorescence and fluoroimmunoassays. The use of mono- clonal antibodies,in immunodiagnosis and of DNA /RNA probes to identify viruses was also discussed in detail. The needfor applicability of these tests at three levels, i.e., field conditions (or primary health care level), local laboratories, and central laboratories, was discussed and their use at thefield level was emphasized. Classical serological techniques have been used for All these tests can be carried out in laboratories that a long time for diagnostic purposes, e.g., for con- are equipped with basic instruments as well as special- firmation of clinical diagnoses, epidemiological ized apparatus (e.g., gamma counters for RIA, ultra- studies, testing of blood donors, etc. Some of these violet microscopes for IMF, etc.), which are usually techniques have been standardized to a high degree of available only in the larger, central laboratories.
    [Show full text]
  • Cytokine Immunocytochemistry Fax (65) 860-1590 Fax (49) 40 531 58 92 Fax (81) 3 541-381-55 E-Mail: [email protected]
    PharMingen International United States Canada PharMingen Europe Japan PharMingen Canada Tel 619-812-8800 Asia Pacific Becton Dickinson GmbH Nippon Becton Dickinson Toll-Free 1-888-259-0187 Orders 1-800-848-6227 BD Singapore HQ PharMingen Europe Company Ltd. Tel 905-542-8028 Tech Service 1-800-825-5832 Tel (65) 860-1478 Tel (49) 40 532 84 48 0 Tel (81) 3 541-382-51 Fax 905-542-9391 Fax 619-812-8888 Cytokine Immunocytochemistry Fax (65) 860-1590 Fax (49) 40 531 58 92 Fax (81) 3 541-381-55 e-mail: [email protected] http://www.pharmingen.com Africa Germany Latin/South America Spain Becton Dickinson Worldwide Inc. Becton Dickinson GmbH BDIS (USA) Becton Dickinson S.A. Reagents and Techniques Tel (254) 2 449 608 HQ PharMingen Europe Tel (408) 954-2157 Tel (34) 91 848 8100 Fax (254) 2 449 619 Tel (49) 40 532 84 48 0 Fax (408) 526-1804 Fax (34) 91 848 8105 Fax (49) 40 531 58 92 Orders for Microscopic Analysis of Cytokine-Producing Cells Australia Malaysia Tel (34) 91 848 8182 Becton Dickinson Pty Ltd Greece Becton Dickinson Sdn Bhd Fax (34) 91 848 8104 Tel (612) 9978-6800 Becton Dickinson Hellas S.A. Tel (03) 7571323 Fax (612) 9978-6850 Tel (30) 1 9407741 Fax (03) 7571153 Sweden Fax (30) 1 9407740 Becton Dickinson AB Austria Mexico Tel (46) 8 775 51 00 Becton Dickinson GmbH Hong Kong Becton Dickinson de Mexico Fax (46) 8 645 08 08 HQ PharMingen Europe Becton Dickinson Asia Ltd Tel (52-5) 237-12-98 Tel (49) 40 532 84 48 0 Tel (852) 2572-8668 Fax (52-5) 237-12-93 Switzerland Fax (49) 40 531 58 92 Fax (852) 2520-1837 Becton Dickinson GmbH Middle East HQ PharMingen Europe Belgium Hungary Becton Dickinson Tel (41) 06 1-385 4422 Becton Dickinson Benelux N.V.
    [Show full text]
  • AG 39: Immunofluorescence Assays (PDF)
    ibidi Application Guide Immunofluorescence Assays The Principle of Immunofluorescence Immunofluorescence Applied: Assays . 2 Experimental Examples . 13 Rat Hippocampal Neuron and Astrocyte Staining 14 Immunofluorescence Staining: Visualization of Endothelial Cell Junctions . 13 A Typical Workflow . 3 Immunostaining of Rat Dorsal Root Ganglionic Experiment Planning and Sample Preparation . 4 Cells and Schwann Cells . 13 Sample Fixation . 4 Adherens Junctions and Actin Cytoskeleton of Cell Permeabilization . 5 HUVECs Under Flow . 14 Blocking . 5 Mitochondria Staining of MDCK cells . 14 Primary Antibody Incubation . 5 Focal Adhesions of Differentiated Mouse Fibroblasts on an Elastic Surface . 15 Secondary Antibody Incubation . 6 Counterstain and Mounting . 7 Microscopy . 7 Troubleshooting . 8 Selected Publications Immunofluorescence C. Xu, et al. NPTX2 promotes colorectal cancer growth and liver With the ibidi Chambers . 9 metastasis by the activation of the canonical Wnt/beta-catenin pathway via FZD6. Cell Death & Disease, 2019, 10.1038/s41419- Comparison of Immunocytochemistry Protocols . 10 019-1467-7 Chambered Coverslips . 11 read abstract Kobayashi, T., et al. Principles of early human development and Channel Slides . 11 germ cell program from conserved model systems. Nature, Chamber Slides . 12 2017, 10.1038/nature22812 read abstract H. Tada et al. Porphyromonas gingivalis Gingipain-Dependently Enhances IL-33 Production in Human Gingival Epithelial Cells. PloS one, 2016, 10.1371/journal.pone.0152794 read abstract N. J. Foy, M. Akhrymuk, A. V. Shustov, E. I. Frolova and I. Frolov. Hypervariable Domain of Nonstructural Protein nsP3 of Venezuelan Equine Encephalitis Virus Determines Cell-Specific Mode of Virus Replication. Journal of Virology, 2013, 10.1128/ jvi.00720-13 read abstract .com The Principle of Immunofluorescence Assays Immunofluorescence (IF) is a powerful approach for getting insight into cellular structures and processes using microscopy .
    [Show full text]
  • 116588NCJRS.Pdf
    If you have issues viewing or accessing this file contact us at NCJRS.gov. " "'- u.s. Department of Justice Federal Bureau of Investigation PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON FORENSIC IMMUNOLOGY FBI ACADEMY QUANTICO, VIRGINIA JUNE 23-26, 1986 Proceedings of the International Symposium on Forensic Immunology co 00 L() \0 u, r-l O§ r-l Ql C. If) 05~ Ql 0- 0 ~ o~ Ql E C/) Ql >. c:0 If) C/) ~ * ....,a: () a: z Ql '*02 Ql iii :5 ...... ....,::> a Ql {ij "...:0- Ql c: !!lc: °E ::>;: B 00 {ij c: 0 ~I::> z~ "e CD ~~ :5 .... ~o- S 1::C: Lt .~ Host Laboratory Division Federal Bureau of Investigation June 23-26, 1986 Forensic Science Research and Training Center FBI Academy Quantico, Virginia NOTICE This publication was prepared by the U. S. Government. Neither the U. S. Government nor the U. S. Department of Justice nor any of their employees makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness or usefulness of any information, apparatus, product or process disclosed, or represents that in use would not infringe privately owned rights. Reference herein to any specific commercial product, process or service by trade name, mark, manufacturer or otherwise does not necessarily constitute or imply its endorsement, recommendation or favoring by the U. S. Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the U. S. Government or any agency thereof. Published by: The Laboratory Division Roger T. Castonguay Assistant Director in Charge Federal Bureau of Investigation U.
    [Show full text]
  • Laboratory Analysis of the Immune Response 859
    Chapter 20 | Laboratory Analysis of the Immune Response 859 Chapter 20 Laboratory Analysis of the Immune Response Figure 20.1 Lab-on-a-chip technology allows immunological assays to be miniaturized so tests can be done rapidly with minimum quantities of expensive reagents. The chips contain tiny flow tubes to allow movement of fluids by capillary action, reactions sites with embedded reagents, and data output through electronic sensors. (credit: modification of work by Maggie Bartlett, NHGRI) Chapter Outline 20.1 Polyclonal and Monoclonal Antibody Production 20.2 Detecting Antigen-Antibody Complexes 20.3 Agglutination Assays 20.4 EIAs and ELISAs 20.5 Fluorescent Antibody Techniques Introduction Many laboratory tests are designed to confirm a presumptive diagnosis by detecting antibodies specific to a suspected pathogen. Unfortunately, many such tests are time-consuming and expensive. That is now changing, however, with the development of new, miniaturized technologies that are fast and inexpensive. For example, researchers at Columbia University are developing a “lab-on-a-chip” technology that will test a single drop of blood for 15 different infectious diseases, including HIV and syphilis, in a matter of minutes.[1] The blood is pulled through tiny capillaries into reaction chambers where the patient’s antibodies mix with reagents. A chip reader that attaches to a cell phone analyzes the results and sends them to the patient’s healthcare provider. Currently the device is being field tested in Rwanda to check pregnant women for chronic diseases. Researchers estimate that the chip readers will sell for about $100 and individual chips for $1.[2] 1.
    [Show full text]
  • Immunocytochemistry of Cytology Specimens for Predictive Biomarkers in Lung Cancer
    905 Review Article on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer Sinchita Roy-Chowdhuri Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Correspondence to: Sinchita Roy-Chowdhuri, MD, PhD. Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 85, Houston, TX 77030, USA. Email: [email protected]. Abstract: With a growing number of predictive biomarkers that have emerged in non-small cell lung carcinoma (NSCLC), there has been a paradigm shift in the management of these patients. Of the various predictive biomarker testing methods, immunohistochemistry (IHC) is the most widely available, cost- effective, and commonly used methods. However, most predictive IHC assays are validated primarily on formalin-fixed paraffin-embedded (FFPE) histologic tissue samples and translating these assays to cytologic specimens requires additional and rigorous validation. This is part due to the lack of standardized processing protocols in cytology resulting in a variety of preanalytic variables that can impact the antigenicity of antibodies used for predictive biomarker testing. The review article discusses the various preanalytical and analytical factors that impact immunocytochemistry (ICC) in cytologic specimens and summarizes the current published literature on ALK, ROS1, PD-L1, and other predictive biomarker ICC in cytology. Keywords: Immunocytochemistry (ICC); lung cancer; cytology; biomarkers; non-small cell lung carcinoma (NSCLC) Submitted Dec 14, 2019. Accepted for publication Dec 25, 2019. doi: 10.21037/tlcr.2019.12.31 View this article at: http://dx.doi.org/10.21037/tlcr.2019.12.31 Predictive biomarkers are markers of therapeutic efficacy, embedded (FFPE) histologic tissue samples, a large fraction the results of which are essential for determining patient of NSCLC patients are diagnosed on cytology samples, care.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA Free Access to Supportive Pharmacopoeial Texts in the Field of Vaccines for Human Use During the Coronavirus Disease (COVID-19) Pandemic
    EUROPEAN PHARMACOPOEIA Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package - October 2020 Published in accordance with the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50) European Directorate Direction européenne for the Quality de la qualité of Medicines du médicament & HealthCare & soins de santé Council of Europe Strasbourg Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package The EDQM is committed to supporting users during the coronavirus disease (COVID-19) pandemic – as well as contributing to the wider global effort to combat the virus – by openly sharing knowledge and providing access to relevant guidance/standards. To support organisations involved in the development, manufacture or testing of COVID-19 vaccines worldwide, many of which are universities and small and medium-sized enterprises, the EDQM is offeringte mporary free access to texts of the European Pharmacopoeia (Ph. Eur.) in the field of vaccines. This package includes quality standards for vaccines which developers can take into account to help build appropriate analytical control strategies for their COVID-19 candidate vaccines and ensure the quality and safety of the final product. Application of such quality requirements may ultimately help to facilitate regulatory acceptance of a subsequent marketing authorisation application. For ease of reading, a summary table listing the pharmacopoeial texts, with information regarding the vaccine types or vaccine platforms concerned (e.g. live attenuated viral vaccine, recombinant viral-vectored vaccines) is provided.
    [Show full text]
  • Immunohistochemical (IHC) Marker Template for Integral Markers in Clinical Trials
    ! "#$%&'()*+,%-.',')'/!01!!!!!!!!!!!!!! -.',')'/!$(2*3,456,'.1!!!!!!!!!!!!!!!!!!!!!!!!!!! Immunohistochemical (IHC) Marker Template For Integral Markers in Clinical Trials This is a template to describe the analytical and clinical performance of an assay that is essential for performance of a trial. It will be used to assess whether assays are ready for use in a trial by Disease Steering Committees and CTEP. The FDA may also use it to evaluate integral assays and diagnostics for their pre-IDE evaluation. Not all parameters may be known a priori. Please enter as much information as you can and N/A for not available or applicable where appropriate. This template requires detailed information that may be known only by laboratorians, scientists who work in clinical laboratories, and should be collaborating closely with clinical trialists. Please be sure to collect the appropriate responses before filling out this form. The template has the following sections with information needed from trialists and laboratorians: 1. Assay, Patient and Specimen Information –Trialists and Laboratorians 2. Primary Antibody Characteristics – Laboratorians 3. Design of Immunohistochemical Assay - Laboratorians 4. Assay Performance – Laboratorians 5. Laboratory Information – Trialists and Laboratorians ! 7! ! "#$%&'()*+,%-.',')'/!01!!!!!!!!!!!!!! -.',')'/!$(2*3,456,'.1!!!!!!!!!!!!!!!!!!!!!!!!!!! Section 1. Assay, Patient and Specimen Information A. Name of marker (Please use HUGO gene or protein name for molecular marker or the Atlas for Genetics in Hematology and Oncology for cytogenetic or FISH markers) HUGO Site: http://www.genenames.org/ Atlas Site: http://atlasgeneticsoncology.org/index.html B. How will assay and its marker be used in clinical trial? Integral Marker Integrated Marker Research Marker • Integral markers are required for the trial to proceed (e.g., patient eligibility, assignment to treatment, stratification, risk classifier or medical decision-making - often requires performance in a CLIA laboratory).
    [Show full text]
  • Neural Cell Markers Neural Cell Markers
    Neural Cell Markers Neural Cell Markers Neurons and glia in neural tissue or cultures are commonly visualized and identified by immunodetection of cell-specific antigenic markers, including transcription factors, enzymes, cytoskeletal proteins, cell surface proteins, and secreted factors. The Bio-Techne brands R&D Systems and Novus Biologicals together offer an unparalleled selection of antibodies directed against these intracellular and cell surface proteins that can be used for the identification and characterization of different neural cell types. R&D Systems also offers a variety of different immunnoassays, including the gold standard Quantikine® ELISA Kits, for detecting secreted molecules. The Bio-Techne brand Tocris offers a novel and exclusive collection of tools, including bioactive small molecules, caged compounds, and fluorescent probes, for the functional identification of neural cells. Table of Contents Neuronal Markers . 1–8 General Markers. .1 Dendritic Markers. 2 Axonal Markers. 2 Presynaptic Markers. 3 Active Zone Markers. 4 Postsynaptic Markers. .4 Growth Cone Markers. .5 Cholinergic Neuron Markers. 6 Dopaminergic Neuron Markers. .6 GABAergic Neuron Markers. 7 Glutamatergic Neuron Markers. .7 Glycinergic Neuron Markers. 8 Serotonergic Neuron Markers. 8 Microglia Markers. 9–12 Steady-State Microglia Markers. .9 M1 Microglia Markers. .10–11 M2 Microglia Markers. 12 Astrocyte Markers. 13 General Markers. 13 Oligodendrocyte Markers. 14–15 Oligodendrocyte Precursor Cell Markers. .14 Immature Oligodendrocyte Markers . 14 Mature, Non-Myelinating Oligodendrocyte Markers. 15 Mature, Myelinating Oligodendrocyte Markers. 15 Additional Tools for Visualizing and Identifying Neural Cells. 16 Conjugated Primary Antibodies. 16 R&D Systems® VisUCyte™ HRP Polymer. 16 R&D Systems® Multiplex Assays . .16 Tocris® Products to Investigate Neural Function.
    [Show full text]
  • IHC/ICC Protocol Guide
    RnDSy-lu-2945 IHC/ICC Protocol Guide This guide provides an introduction to the techniques, protocols, and troubleshooting methods that lead to a successful immunohistochemistry (IHC) or immunocytochemistry (ICC) experiment. Contributors include scientists from our IHC/ICC core facility who have experience qualifying thousands of antibodies for these applications and our expert technical service team who have guided researchers through a range of IHC/ICC-related issues. To view these protocols online, please visit rndsystems.com/IHCProtocol. To learn more about R&D Systems brand antibodies, please visit rndsystems.com/Antibodies. This page also allows you to search for primary and secondary antibodies for your research. Use the drop-down menu to filter by species, application, and conjugate. Cover images generated using R&D Systems brand antibodies. To view the continuously updated IHC/ICC image gallery, please visit rndsystems.com/IHCimages. Table of Contents Introduction to the IHC/ICC Method. .1–11 IHC/ICC Protocols. 13–22 Designing a Successful IHC/ICC Experiment. 3 Making a 4% Formaldehyde Solution in PBS .....................14 Sample Preparation. 4 Preparation of Gelatin-Coated Slides for Histological Tissue Sections .............................. 15 Paraffin-Embedded Tissue Chromogenic Staining of Tissue Sections Frozen Tissue Using HRP-DAB Detection ................................16–17 Cell Samples Slide Preparation Fixation. 5 Chromogenic Staining Using HRP-DAB Detection Formaldehyde IHC Staining of Tissue Sections for Fluorescence Microscopy ...... 18 Alcohols Antigen Retrieval Using Heat-Induced Epitope Retrieval (HIER) ..... 19 Acetone Preparation of Coverslips and Cell Fixation for ICC ............... 20 Fixation of Tissues Coverslip Preparation Using Gelatin Fixation of Cultured Cells Preparation and Fixation of Cells on Coverslips Preventing Non-Specific Staining .
    [Show full text]
  • Immunocytochemistry (ICC) Handbook
    Novus-lu-2945 Immunocytochemistry (ICC) Handbook Learn more | novusbio.com Learn more | novusbio.com Excitation/ Emission Laser Conjugate Notes Emission Color (Excitation Source) DyLightTM 405 400/420 Violet Violet (405 nm) Bright and photostable Alexa Fluor® 405 401/421 Violet Violet (405 nm) Best when used with more abundant targets Can be used with DyLightTM 488, 594 and 647 DyLightTM 350 353/432 Violet-Blue Ultraviolet (355 nm) in multiplexing Often used with Alexa Fluor® 488, 594 and 647 in Alexa Fluor® 350 346/442 Violet-Blue Ultraviolet (355 nm) multiplexing, best for high-abundance targets Brighter, photostable replacement for FITC; DyLightTM 488 493/518 Green Blue (488) not suitable for use with GFP Photostable over a broad pH range; Alexa Fluor® 488 495/519 Green Blue (488) replaces FITC Small organic fluorophore; cannot be used with FITC 495/519 Green Blue (488) DyLightTM 488, Alexa Fluor® 488 or GFP Violet Superior alternative to Pacific Orange; good choice DyLightTM 405LS 397/572 Yellow (405 nm) for multicolor applications on the violet laser Photostable over a broad pH range; Alexa Fluor® 546 556/573 Yellow Yellow-Green (561 nm) brighter than Cy3 DyLightTM 550 562/576 Yellow Yellow-Green (561 nm) Subject to photobleaching; can be excited by the PE 565/578 Yellow Yellow-Green (561 nm) 488, 532, and 561nm lasers on flow cytometers Very bright fluorescence; use a tunable dye laser Texas Red® 595/613 Orange Yellow-Green (561 nm) to avoid leaking when multiplexed with PE Alexa Fluor® 594 590/617 Orange Yellow-Green (561 nm) Better photostability than Texas Red DyLightTM 650 654/673 Red Red (633 nm) Bright fluorescent protein; do not use with APC 650/660 Red Red (633 nm) DyLightTM 650 due to overlapping emission spec- tra Extremely photostable, good Alexa Fluor® 647 650/665 Red Red (633 nm) replacement for Cy5 or APC Some fluorescence quenching when Cy5TM 647/665 Red Red (633 nm) conjugated DyLightTM is a registered trademark of Thermo Fisher Scientific Inc.
    [Show full text]